Oral bexarotene in the treatment of cutaneous T-cell lymphoma

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1056-1065

  Wong, S F ^a  

^a NONE   (United States)

Author keywords

Bexarotene; Cutaneous T cell lymphoma

Indexed keywords

BEXAROTENE; ERYTHROMYCIN; GEMFIBROZIL; ITRACONAZOLE; KETOCONAZOLE; PHENOBARBITAL; PHENYTOIN; RETINOID X RECEPTOR; RIFAMPICIN;

ACUTE PANCREATITIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; LIVER FAILURE; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; SUBDURAL HEMATOMA; T CELL LYMPHOMA;

EID: 0034826845     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002800103500903     Document Type: Review

References (44)

1. Mycosis fungoides and the Sézary syndrome
2. Cutaneous T-cell lymphomas
3. Primary cutaneous T-cell lymphoma: Review and current concepts
4. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
5. Clinical stage IA (limited patch and plaque) mycosis fungoides: A long-term outcome analysis
6. Prognosis in cutaneous T-cell lymphoma by skin stage: Long term survival in 489 patients
7. Oral bexarotene is safe and effective in a Phase II-III clinical trial in refractory or persistent early stage CTCL
8. Phase II-III clinical trial of bexarotene capsules demonstrated efficacy and safety for patients with refractory or persistent early stage CTCL
9. Phase II-III clinical trial of bexarotene capsules in patients with refractory advanced stage CTCL demonstrates efficacy and safety
10. Oral bexarotene benefits patients with refractory advanced stage CTCL
11. Initial clinical trial of a selective retinoids X receptor ligand, LGD1069
12. A Phase I study of LGD 1069 in adults with advanced cancer
13. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids
14. Palliation and remission of erythrodermic cutaneous T-cell lymphoma with a novel oral RXR-selective retinoid
15. Targretin approved for advanced CTCL following ODAC recommendation
16. Targretin (bexarotene) capsules
17. Central hypothyroidism associated with retinoid X receptor-selective ligands
18. Evaluation of the cytochrome P450 isoenzymes involved in the metabolism of Targretin, an RXR-selective retinoid
19. Topical corticosteroids for mycosis fungoides
20. Cutaneous T-cell lymphoma: Update of treatment
21. Topical treatment of early cutaneous T-cell lymphoma
22. Total skin electron beam therapy in the management of mycosis fungoides
23. Home UV phototherapy for early mycosis fungoides: Long-term follow-up observations in thirty-one patients
24. Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up
25. Topical carmustine (BCNU) for cutaneous T-cell lymphoma
26. Treatment of erythrodermic cutaneous T-cell lymphoma by extracorporeal photochemotherapy
27. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone
28. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients
29. Chemotherapy for mycosis fungoides and the Sézary syndrome
30. Nucleoside analogs in the systemic treatment of mycosis fungoides/Sézary syndrome
31. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: A clinical follow-up study of 81 patients treated with COP or CHOP
32. Interferon treatment of cutaneous T-cell lymphoma
33. Treatment of cutaneous T cell lymphoma with retinoids
34. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome
35. Phase 11 trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome
36. The benefits of topical bexarotene in patients with refractory or persistent early stage cutaneous T-cell lymphoma: Results of the phase 3 clinical trial
37. Gemcitabine treatment in pretreated cutaneous-T-cell lymphoma: Experience in 44 patients
38. Emerging new therapies for cutaneous T-cell lymphoma
39. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand
40. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure
41. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma